Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today's News: Middle East.
Press releases published on May 31, 2025
Robex gibt Abschluss des Börsengangs bekannt
GlobeNewswire
·
May 31, 2025
STADT QUÉBEC, May 31, 2025 (GLOBE NEWSWIRE) -- Der westafrikanische Goldproduzent und -erschließer Robex Resources Inc („Robex“ oder das „Unternehmen“) (TSX-V: RBX) freut sich bekannt zu geben, dass das Unternehmen den Börsengang an der Australian …
Robex annonce la finalisation de son introduction en bourse
GlobeNewswire
·
May 31, 2025
QUÉBEC, 31 mai 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. (« Robex » ou la « Société ») (TSX-V : RBX), producteur et développeur aurifère ouest-africain, a le plaisir d’annoncer le succès de son introduction sur la bourse australienne (« ASX ») avec 38 …
Crypto Bubbles Come and Go: How Bitcoin Solaris’s Technology Aims for Stable, Long-Term Appreciation
GlobeNewswire
·
May 31, 2025
TALLINN, Estonia, May 31, 2025 (GLOBE NEWSWIRE) -- As Phase 5 of its limited presale nears completion, Bitcoin Solaris (BTC-S) is gaining momentum for all the right reasons. With its innovative Nova App poised for launch and over $1.2 million raised from …
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
GlobeNewswire
·
May 31, 2025
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
GlobeNewswire
·
May 31, 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, …
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
GlobeNewswire
·
May 31, 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, …
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS…
GlobeNewswire
·
May 31, 2025
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no …
Lancaster Resources Announces Closing Conditions Met for Lake Cargelligo Acquisition
GlobeNewswire
·
May 31, 2025
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF0) (“Lancaster”), is pleased to announce it has received approval from the Canadian Securities Exchange to complete the acquisition of …